乳腺癌非典型 B 细胞的预后价值。

IF 14.3 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2024-11-01 Epub Date: 2024-10-01 DOI:10.1016/j.trecan.2024.09.009

Esmeralda García-Torralba, Lorenzo Galluzzi, Aitziber Buqué

引用次数: 0

摘要

人们对肿瘤浸润性 B 细胞对乳腺癌（BRCA）预后的影响仍然知之甚少。Yang等人的最新研究发现，活化的Fc受体样4（FCRL4）+B细胞是一种非典型、克隆性扩增的细胞群，它与包括BRCA在内的各种肿瘤患者总生存率的提高有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Prognostic value of atypical B cells in breast cancer.

The impact of tumor-infiltrating B cells on breast cancer (BRCA) outcomes remains poorly understood. Recent findings from Yang et al. identify an atypical, clonally expanded population of activated Fc receptor-like 4 (FCRL4)⁺ B cells that is associated with improved overall survival in patients affected by various tumor types, including BRCA.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.